817 studies found for:    crf1
Show Display Options
Rank Status Study
1 Completed Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^
Conditions: Alcohol-Related Disorders;   Alcohol Dependence;   Alcoholism;   Anxiety Disorder
Interventions: Drug: Pexacerfont;   Drug: Placebo
2 Recruiting Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers
Condition: Anxiety Disorders
Intervention:
3 Active, not recruiting Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
Condition: Stress Disorders, Post-Traumatic
Interventions: Drug: GSK561679;   Drug: Placebo
4 Completed Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome (IBS)
Intervention: Drug: GW876008
5 Recruiting Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety
Condition: Alcohol Dependence
Interventions: Drug: GSK561679;   Drug: Placebo
6 Completed Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
Condition: Irritable Bowel Syndrome (IBS)
Intervention: Drug: GW876008
7 Terminated A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
Condition: Irritable Bowel Syndrome
Intervention: Drug: GW876008 and GSK561679
8 Active, not recruiting Analyzing Female Trauma Exposed Responses to a Medication
Condition: Stress Disorders, Post-traumatic
Interventions: Drug: GSK561679;   Drug: Placebo
9 Completed Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
Conditions: Irritable Colon;   Irritable Bowel Syndrome (IBS)
Interventions: Drug: GW876008 200mcg;   Drug: GW876008 20mcg;   Other: Placebo
10 Recruiting Pexacerfont for Stress-induced Food Craving
Conditions: Daily Oral Pexacerfont for 28 Days (300 mg/Day Loading Dose for 7 Days, Followed;   Placebo
Intervention: Drug: Pexacerfont
11 Completed A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
Condition: Social Anxiety Disorder
Interventions: Drug: GSK561679;   Drug: GW876008;   Drug: alprazolam
12 Recruiting A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
Condition: Colon Cancer
Intervention:
13 Completed Gender and Neural Substrates of Stress and Craving
Condition: Cocaine Dependence
Intervention: Drug: Acthrel
14 Completed Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers
Conditions: Vascular Disease;   Heart Disease
Intervention: Drug: Astressin 2B
15 Suspended Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 2)
Conditions: Vascular Disease;   Heart Disease
Interventions: Drug: Urocortin 2, Urocortin 3;   Drug: Saline placebo
16 Completed Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease
Conditions: Type 1 Diabetes Mellitus;   End-stage Renal Disease
Intervention: Procedure: simultaneous islet-kidney transplantation
17 Completed
Has Results
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
Conditions: End-Stage Renal Disease;   Hemodialysis
Intervention: Drug: CP-690,550
18 Not yet recruiting The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
Condition: End-stage Renal Disease
Interventions: Other: Eu- and hyperglycemic clamp;   Other: Arginine test
19 Withdrawn Vitamin D and Carboxy PTH Fragments in Coronary Calcification
Conditions: Coronary Calcification;   Endstage Renal Disease;   Parathyroid Hormone
Interventions: Drug: Doxercalciferol administration;   Drug: Doxercalciferol administered by 1-84-7-84
20 Completed
Has Results
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
Conditions: Diabetes Mellitus, Type 2;   End-Stage Kidney Disease
Interventions: Drug: Sitagliptin;   Drug: Glipizide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years